Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab Plus Chemotherapy in Resectable Stage IIIA-IIIB NSCLC
NCT06123754Phase 3Recruiting
- Sponsor
- 3D Medicines Inc.
- Start
- Nov 2023
- Primary completion
- Dec 2027
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of envafolimab in non-small cell lung cancer (NSCLC), sponsored by 3D Medicines Inc.. Started Nov 2023; status: recruiting.
02
Drugs
envafolimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06123754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06123754.